- 1 Disease Entity
- 2 Diagnosis
- 3 Clinical diagnosis
- 4 Management
- 5 Additional Resources
- 6 See also
- 7 References
Hyphema of iris and ciliary body - ICD-9 CM Diagnosis Code: 364.41
Accumulation of red blood cells within the anterior chamber is referred to as a hyphema. A small amount of blood that is only evident under close microscopic examination is referred to as a microhyphema. A majority of patients present with a history that correlates to the etiology. A history of trauma or recent ocular surgery are the most common risk factors. However, a seemingly spontaneous hyphema can result at times from other causes. Despite the degree or etiology, the management of a hyphema and its associated complications can be challenging for any ophthalmologist.
Hyphema can occur after blunt or lacerating trauma, after intraocular surgery, spontaneously (e.g., in conditions such as rubeosis iridis, juvenile xanthogranuloma, iris melanoma, myotonic dystrophy, keratouveitis (e.g., herpes zoster), leukemia, hemophilia, von Willebrand disease, and in association with the use of substances that alter platelet or thrombin function (e.g., ethanol, aspirin, warfarin).5
Blunt trauma is the most common cause of a hyphema. Compressive force to the globe can result in injury to the iris, ciliary body, trabecular meshwork, and their associated vasculature. The shearing forces from the injury can tear these vessels and result in the accumulation of red blood cells within the anterior chamber.
Hyphemas can also be iatrogenic in nature. Intraoperative or postoperative hyphema is a well known complication to any ocular surgery. Rarely, the placement of an intraocular lens within the anterior chamber can result in chronic inflammation, secondary iris neovascularization, and recurrent hyphemas, known as uveitis-glaucoma-hyphema (UGH) syndrome.1 This is a direct result of a malpositioned or rotating anterior chamber intraocular lens. This condition has also been reported in posterior chamber, sulcus, and suture-fixated intraocular lenses.1,4 Additionally, a hyphema resulting from an ocular laser procedure is a possible adverse event. Postlaser hyphema is not uncommon after the use of the Nd:YAG laser for a peripheral iridectomy. Typically the resulting hyphema is minimal and self-limited.
A spontaneous hyphema, commonly confused with a traumatic hyphema, is likely secondary to neovascularization (eg, diabetes mellitus, ischemia, cicatrix formation), ocular neoplasms (eg, retinoblastoma), uveitis, or vascular anomalies (eg, juvenile xanthogranuloma).2
Diagnosis is made with slit-lamp examination of the anterior chamber. A large hyphema can be noted with pen-light examination alone.
A majority of patients will have a history consistent with recent ocular trauma or surgery. However, in the setting of a spontaneous hyphema further investigation may be required. It is important to ask the patient if they have a past history of bleeding diathesis or anticoagulation therapy, which can be a rare risk factor in the development of a hyphema. It is also important to discuss factors that may predispose the patient to ocular complications of a hyphema, such as a clotting disorders or sickle cell disease.
The examination for a hyphema should consist of a routine ophthalmic work-up (visual acuity, pupillary examination, intraocular pressure, slit-lamp examination) as well as a gonioscopy to evaluate the condition of the angle and trabecular meshwork. This is important especially in the setting of ocular trauma to gain an understanding of the extent of the trauma. This can be delayed until after the critical 5-day, high-risk, re-bleed period, particularly when doing dynamic gonioscopy. Angle abnormalities such as peripheral anterior synechiae (PAS) and angle recession may commonly be found.2 It is also critical to measure the height of the hyphema from the inferior limbus.
Figure 1. Slit-lamp photo illustrating conjunctival injection, corneal edema with Descemet membrane folds, and a 1 mm hyphema after blunt force trauma from an airbag deployment.
Figure 2. Slit-beam photo with hyphema visible within the inferior anterior chamber. (Same eye as Figure 1)
Figure 3. Iris neovascularization in a patient with proliferative diabetic retinopathy with a resultant spontaneous hyphema.
Figure 4. Slit-beam photo with hyphema visible within the inferior anterior chamber. (Same eye as Figure 3)
A large hyphema can be noted with pen-light examination alone. The height and color of the hyphema should be documented. Height can be measured in millimeters from the inferior corneal limbus. Color can vary from red to black depending on the time frame of the hyphema. Blood that has clotted will appear darker in appearance (black). It is important to evaluate intraocular pressure.
Hyphemas can be graded from I-IV in the following manner:2
Grade 0: No visible layering, but red blood cells within the anterior chamber (microhyphema)
Grade I: Layered blood occupying less than one third of the anterior chamber
Grade II: Blood filling one third to one half of the anterior chamber
Grade III: Layered blood filling one half to less than total of the anterior chamber
Grade IV: Total clotted blood, often referred to as blackball or 8-ball hyphema
Symptoms associated with a hyphema can be variable depending on the etiology. Typically patients will complain of associated blurry vision and ocular distortion. In the setting of trauma or secondary intraocular pressure elevation, patients may complain of pain, headahce, and photophobia.
All African American patients with a hyphema should be screened for sickle cell trait or disease with a sickle cell prep. A greater risk of trabecular meshwork obstruction with red blood cells exists while in the sickled state. Resultant elevated intraocular pressure levels put the patient at greater risk of permanent vision loss from optic nerve damage. Hemoglobin electrophoresis can be used as a confirmatory test for a positive sickle cell prep.
1. Traumatic hyphema: Blunt trauma to the eye may result in injury to the iris, pupillary sphincter, angle structures, lens, zonules, retina, vitreous, optic nerve, and other intraocular structures. Blunt trauma to the eye is associated with a rapid, marked elevation in intraocular pressure with sudden distortion of intraocular structures.6 As a result, normal vasculature within the anterior chamber is exposed to shearing forces that are responsible for hyphema formation.
2. Hyphema secondary to ocular surgery or laser: Hyphema is a risk factor for any intraocular surgery performed; however, rare in routine elective cases. The incidence is higher in patients with a past medical or ocular history that predisposes them to irregular vasculature within the anterior chamber (e.g., ocular ischemia and neovascularization).
3. Neovascularization: Abnormal blood vessel growth on the iris, ciliary body, or within the angle may lead to the development of a hyphema. Typically, this neovascularization is a direct result of posterior segment ischemia. Retinal microvascular disease in diabetic patients is by far the most common etiology. Vascular endothelial growth factor (VEGF) up regulation from ischemic tissue disperses within the eye and allows for anterior segment neovascular growth. Retinal ischemia also can occur subsequently to retinal arterial or venous occlusion. Another cause of the neovascularization is carotid stenosis, which can lead to ocular ischemia (ocular ischemic syndrome).2
4. Neoplastic: Tumor growth is dependent on an extensive vascular supply. Ocular neoplastic disease such as melanoma (iris, ciliary body, and / or choroidal) or pediatric retinoblastoma can predispose patients to the development of a hyphema.
5. Inflammatory / Infectious: Common intraocular inflammatory conditions that can result in neovascularization and resultant hyphema are herpetic (HSV and VZV) uveitis and Fuch's heterochromic iridocyclitis.
6. Vascular anomaly: A rather rare disease that is commonly thought of when evaluating pediatric patients with a hyphema is juvenile xanthogranuloma (JXG). It is mainly a skin disorder characterized by a typically, raised, orange lesion, occurring either singly or in crops and regresses spontaneously with occasional involvement of the eyes. The most common ocular finding is diffuse or discrete iris nodules, which could be quite vascular and may bleed spontaneously, resulting in hyphema.7
Uncomplicated hyphemas should be managed conservatively, with an eye shield, limited activity, and head elevation.1 Maintaining head elevation of at least 45 degrees will allow the hyphema to settle inferiorly within the anterior chamber. This avoids central visual obstruction, as well as limits both corneal endothelial and trabecular meshwork exposure to red blood cells. Most patients can be managed in an outpatient setting with close follow-up to evaluate vision, hyphema regression, and intraocular pressure. However, hospitalization should be considered for noncompliant patients, patients with bleeding diathesis or blood dyscrasia, patients with severe ocular or orbital injuries, and patients with concomitant intraocular pressure elevations with known sickle cell disease.8 Pain control for all patients with a hyphema should not include aspirin-containing products or NSAIDs, as these can increase the risk for further bleeding.
Medical treatment for an isolated hyphema typically is topical. Topical corticosteroids (systemic for severe cases) may reduce associated inflammation, although the effect on the risk for rebleeding is debatable. Topical cycloplegic agents are also useful for patients with significant ciliary spasm or photophobia. In the setting of intraocular pressure elevation, topical aqueous suppressants are first line agents for pressure management (beta-blockers and alpha-agonists). Systemic carbonic anydrase inhibitors and hyperosmotic agents (acetazolamide or mannitol) may be required if topical management fails to control the pressure. If this is the case, the patient will likely require surgical intervention.
It is important to note that carbonic anhydrase inhibitors are generally avoided in the treatment of pressure elevations because these agents may increase the sickling tendency in the anterior chamber of patients with sickle cell hemoglobinopathies by increasing aqueous acidity.1 Also, systemic hyperosmotic agents may induce a sickle crisis in dehydrated patients with sickle cell disease, and should be avoided in these patients for this reason.
Systemic and topical aminocaproic acid (ACA) have been recommended in various studies as treatment options to avoid secondary hemorrhage in hyphema patients.1,2,5,11 ACA is a derivative and analog of the amino acid lysine, and competitively inhibits plasmin, an important protein enzyme involved in fibrinolysis. If secondary hemorrhages are the result of lysis and retraction of a clot that has produced an occlusion of the traumatized vessel, then prevention of normally occurring clot lysis for 5-6 days should be advantageous to allow the injured blood vessel to more completely repair its integrity.2 Antifibrinolytics such as ACA are not routinely used in the treatment of hyphemas, but may be beneficial in patients at higher risk for rebleeding or other hyphema associated complications.
If the intraocular pressure is not adequately controlled with medical management, or the patient develops further ocular complications (corneal blood staining, rebleed), surgical treatment may be necessary.
A majority of hyphemas will resolve with medical management alone. Approximately 5 percent of patients with traumatic hyphema require surgery.3 The patient can typically be monitored for the first 4 days with medical treatment alone to allow for spontaneous resolution. After that point, surgical intervention may be indicated in the setting of uncontrolled glaucoma, corneal blood staining, the persistence of a large or total hyphema, and active bleeding in the anterior chamber.9 Uncontrolled intraocular hypertension is defined as greater than or equal to 50 mmHg for more than five days, or more than 25 mmHg for more than 24 hours in patients with sickle hemoglobinopathy despite maximal medical therapy.5 Patients with sickle cell hemoglobinopathies and even those with sickle cell trait require surgical intervention if intraocular pressure is not controlled within 24 hours.2 If a large hyphema results in complete visual obstruction in a pediatric patient, amblyopia could result. In these younger patients, early surgical intervention may be justified to avoid this visual complication.
Options for surgical intervention consist of anterior chamber irrigation and aspiration through a small incision (anterior chamber washout), hyphema evacuation with closed vitrectomy instrumentation, or clot irrigation with a filtering procedure (trabeculectomy). Additionally, an anterior chamber paracentesis can be performed for temporarizing control of elevevated intraocular pressure. If a total hyphema is present, it's possible that pupillary block could occur, and a peripheral iridectomy may be indicated during the time of surgery. An anterior chamber washout with irrigation and aspiration is commonly performed first.1 If intraocular pressure remains uncontrolled, a trabeculectomy along with repeat anterior chamber washout is indicated. A trabeculectomy is generally not performed for smaller hyphemas, but is used by some clinicians as the initial surgical approach (with concomitant peripheral iridectomy and anterior chamber washout).2
Postoperative hyphemas may be seen at the time of surgery or within the first 2-3 days after surgery. If bleeding is identified intraoperatively, it must be identified and coagulated if it does not cease on its own.2
1. Obstruction of trabecular meshwork with associated intraocular pressure elevation
2. Peripheral anterior synechiae (PAS)
3. Posterior synechiae
4. Corneal bloodstaining
6. Pupillary block
7. Amblyopia (pediatric patients)
Prognosis is dependent on the etiology and whether the patient developed an associated complication from the hyphema. These patients should be monitored closely to ensure adequate resolution of the hyphema without the development of visually debilitating complications. Additionally, patients with a history of ocular trauma require routine follow-up with gonioscopic examination because of the potential for development of angle-recession glaucoma.
All Images are Courtesy of The Krieger Eye Institute (KEI) at Sinai Hospital of Baltimore, along with Dr. Gregory Oldham.
1. American Academy of Ophthalmology link: http://www.aao.org/theeyeshaveit/trauma/hyphema.cfm
2. Want a brief, patient-friendly summary of hyphema? Check out http://www.geteyesmart.org/eyesmart/diseases/hyphema.cfm
1. Basic and Clinical Science Course. Glaucoma. pp 114-116; 2009-10.
2. Sheppard, John D. Jr, et al. Hyphema. Medscape Reference. 2009.
3. Andreoli, Christopher M., et al. Traumatic hyphema: Epidemiology, anatomy, and pathophysiology. UpToDate. 2011.
4. Condon, Garry P. Single-Piece Syndrome. Glaucoma Today. June 2011.
5. Walton W, et al. Management of traumatic hyphema. Survey of Ophthalmology. 2002 Jul-Aug; 47(4): 297-334.
6. Inci Irak-Dersu, et al. Glaucoma, Hyphema. Medscape Reference. 2009.
7. P Vijayalakshmi, et al. Bilateral spontaneous hyphaema in juvenile xanthogranuloma. Indian Journal of Ophthalmology. 2006. Vol 56 (1): 45-46.
8. Ehlers, Justis P. and Shah, Chirag P. The Wills Eye Manual. Office and Emergency Room Diagnosis and Treatment of Eye Disease. 5th Edition. 2008. pp 20-22.
9. Wilson FM. Traumatic hyphema: pathogenesis and management. Ophthalmology. 1980;87:910-919.
10. Diddie KR. Total hyphema evacuation by vitrectomy instrumentation. Ophthalmology. 1981;88:917-921.
11. Beiran, Itzchak, et al. Characteristics and Functional Outcome of Traumatic Hyphema without Routine Administration of Aminocaproic Acid. IMAJ. Nov 2002. Vol 4(1009-1010).